Persongen Biotherapeutics (suzhou) Co., Ltd.
Clinical trials sponsored by Persongen Biotherapeutics (suzhou) Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New CAR-T therapy takes on tough blood cancers Results expected Sep 2026 (estimated)
- Experimental CAR-T therapy targets tough T-Cell cancers in new trial Results expected Oct 2026 (estimated)
- New shot aims to control Hard-to-Treat blood cancers Results expected Dec 2026 (estimated)
-
Experimental CAR-T therapy targets tough T-Cell cancers in new trial
Disease control Recruiting nowThis Phase 2 trial tests a single infusion of PA3-17, a CAR-T cell therapy that targets CD7 on cancer cells, in 100 adults with relapsed or refractory T-lymphoblastic leukemia or lymphoma. Participants receive the treatment after a short chemotherapy prep, and researchers will mo…
Phase 2 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New shot targets tough blood cancers in early trial
Disease control Recruiting nowThis study tests a new injection called UTAA07 for adults with CD7-positive blood cancers that have come back or not responded to treatment. The main goals are to check safety and find the best dose. Only 15 people will take part in this early-stage trial.
Early phase 1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new cell therapy called LV009 for people with certain blood cancers (lymphoma and leukemia) that have come back or not responded to treatment. The therapy uses a patient's own immune cells, modified to target cancer cells. The main goal is to c…
Early phase 1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New shot aims to control Hard-to-Treat blood cancers
Disease control Recruiting nowThis early study tests a new treatment called LV009 injection in 10 adults whose blood cancers (certain types of lymphoma or leukemia) have returned or stopped responding to standard therapy. The main goal is to check if the treatment is safe. Participants receive the injection a…
Phase 1 • Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC